Cim Investment Mangement Inc. boosted its holdings in Blueprint Medicines Corp (NASDAQ:BPMC) by 82.7% in the 3rd quarter, Holdings Channel reports. The firm owned 6,270 shares of the biotechnology company’s stock after purchasing an additional 2,839 shares during the period. Cim Investment Mangement Inc.’s holdings in Blueprint Medicines were worth $489,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. NumerixS Investment Technologies Inc raised its position in Blueprint Medicines by 750.0% in the 2nd quarter. NumerixS Investment Technologies Inc now owns 5,100 shares of the biotechnology company’s stock valued at $311,000 after purchasing an additional 4,500 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in Blueprint Medicines by 7.4% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 25,236 shares of the biotechnology company’s stock valued at $1,602,000 after buying an additional 1,740 shares during the period. grace capital acquired a new position in Blueprint Medicines in the 2nd quarter valued at $171,000. Renaissance Technologies LLC acquired a new position in Blueprint Medicines in the 2nd quarter valued at $15,603,000. Finally, Bollard Group LLC increased its stake in Blueprint Medicines by 38.6% in the 2nd quarter. Bollard Group LLC now owns 53,000 shares of the biotechnology company’s stock valued at $3,364,000 after buying an additional 14,750 shares during the period.

Shares of BPMC opened at $51.88 on Wednesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 10.05 and a current ratio of 10.05. Blueprint Medicines Corp has a 1 year low of $50.51 and a 1 year high of $109.00.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Tuesday, October 30th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($0.09). Blueprint Medicines had a negative net margin of 455.15% and a negative return on equity of 36.72%. The firm had revenue of $1.10 million during the quarter, compared to analyst estimates of $1.87 million. During the same period in the prior year, the firm posted ($0.96) earnings per share. The business’s quarterly revenue was down 86.4% compared to the same quarter last year. Sell-side analysts anticipate that Blueprint Medicines Corp will post -5.25 earnings per share for the current fiscal year.

In other news, insider Marion Dorsch sold 2,300 shares of the company’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $70.47, for a total transaction of $162,081.00. Following the transaction, the insider now directly owns 2,300 shares of the company’s stock, valued at approximately $162,081. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Jeffrey W. Albers sold 20,000 shares of the company’s stock in a transaction on Monday, November 5th. The stock was sold at an average price of $63.49, for a total transaction of $1,269,800.00. Following the transaction, the chief executive officer now directly owns 20,000 shares in the company, valued at $1,269,800. The disclosure for this sale can be found here. Corporate insiders own 3.15% of the company’s stock.

Several brokerages have issued reports on BPMC. BidaskClub raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Saturday, September 1st. Leerink Swann began coverage on shares of Blueprint Medicines in a research note on Tuesday, September 25th. They issued an “outperform” rating and a $105.00 price objective on the stock. ValuEngine raised shares of Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 17th. Wedbush reissued an “outperform” rating and issued a $101.00 price objective on shares of Blueprint Medicines in a research note on Monday, October 8th. Finally, Cowen reissued a “buy” rating on shares of Blueprint Medicines in a research note on Sunday, October 7th. Two analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $97.14.

WARNING: This piece was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2018/11/21/cim-investment-mangement-inc-grows-position-in-blueprint-medicines-corp-bpmc.html.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Featured Story: Moving Average (MA)

Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Corp (NASDAQ:BPMC).

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.